
NRBO
Healthcare · Biotechnology · $20.3M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 11, 2024 | Before the open | -0.73 | -0.55 | +24.7% |
| Aug 14, 2024 | Before the open | -1.12 | -1.85 | -65.2% |
| May 9, 2024 | Before the open | -3.63 | -1.32 | +63.6% |
| Mar 28, 2024 | Before the open | -0.78 | -2.28 | -192.3% |
| Nov 13, 2023 | After the close | -0.11 | -0.09 | +18.2% |
| Aug 9, 2023 | After the close | -0.13 | -0.02 | +84.6% |
| May 12, 2023 | After the close | -0.63 | -0.10 | +84.1% |
| Mar 30, 2023 | After the close | -1.20 | -1.82 | -51.7% |
| Nov 14, 2022 | After the close | -5.10 | -3.50 | +31.4% |
| Aug 12, 2022 | After the close | -5.10 | -0.12 | +97.6% |
| May 13, 2022 | After the close | -0.15 | -0.17 | -13.3% |
| Mar 31, 2022 | After the close | — | -5.19 | — |
| Nov 15, 2021 | Before the open | -5.40 | -4.80 |
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1…
| +11.1% |
| Aug 16, 2021 | Before the open | -4.50 | -5.40 | -20.0% |
| Apr 15, 2021 | After the close | -5.70 | -36.00 | -531.6% |
| Nov 13, 2020 | After the close | -5.10 | -5.70 | -11.8% |
| Aug 11, 2020 | After the close | -5.70 | -4.50 | +21.1% |
| May 20, 2020 | After the close | -3.00 | -9.00 | -200.0% |
| Mar 30, 2020 | After the close | -6.00 | -101.10 | -1585.0% |
| Nov 8, 2019 | Before the open | -0.11 | -6.00 | -5354.5% |
| Aug 9, 2019 | Before the open | -116.25 | -150.00 | -29.0% |
| May 9, 2019 | After the close | -0.42 | -6.75 | -1507.1% |
| Mar 15, 2019 | Before the open | -307.50 | -195.00 | +36.6% |
| Nov 8, 2018 | After the close | -354.37 | -322.50 | +9.0% |
| Aug 13, 2018 | After the close | -409.50 | -352.50 | +13.9% |
| May 8, 2018 | After the close | -496.87 | -435.00 | +12.5% |
| Mar 15, 2018 | After the close | -519.00 | -472.50 | +9.0% |